HBM Holdings (HBM Holdings) Other Long-Term Liabilities : $16.14 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Other Long-Term Liabilities?

HBM Holdings's other long-term liabilities for the quarter that ended in Dec. 2023 was $16.14 Mil.

HBM Holdings's quarterly other long-term liabilities declined from Dec. 2022 ($16.06 Mil) to Jun. 2023 ($15.84 Mil) but then increased from Jun. 2023 ($15.84 Mil) to Dec. 2023 ($16.14 Mil).

HBM Holdings's annual other long-term liabilities increased from Dec. 2021 ($2.31 Mil) to Dec. 2022 ($16.06 Mil) and increased from Dec. 2022 ($16.06 Mil) to Dec. 2023 ($16.14 Mil).

HBM Holdings Other Long-Term Liabilities Historical Data

The historical data trend for HBM Holdings's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Other Long-Term Liabilities Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial						-	-	-	-	-

HBM Holdings Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

HBM Holdings Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings (HBM Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

02142:Hong Kong

Address

420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire • 01-19-2024